HIN
Enhancing the brain’s lymphatic system when administering immunotherapies may lead to better clinical outcomes for Alzheimer’s disease patients, according to a new study in mice. Results published April 28 in Nature suggest that treatments such as the immunotherapies BAN2401 or aducanumab might be more effective when the brain’s lymphatic system can better drain the amyloid-beta protein that accumulates in the brains of those living with Alzheimer’s. Major funding for the research was provided by the National Institute on Aging (NIA), part of the National Institutes of Health, and all study data is now freely available to the broader scientific community.
Latest Articles freerepublic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freerepublic.com Daily Mail and Mail on Sunday newspapers.
Explained: There’s Higher Risk Of Death And Disease In Covid Survivors
According to a study published by researchers at Washington University School of Medicine in St Louis, Covid survivors, including, those not sick enough to be hospitalised have an increased risk of death in the six months following diagnosis with the virus. Representational image Outlook Web Bureau 2021-04-27T07:59:13+05:30 Explained: There’s Higher Risk Of Death And Disease In Covid Survivors outlookindia.com 2021-04-27T08:02:14+05:30
Also read
As coronavirus cases are increasing, it has become clear that the survivors even those who had mild cases continue to suffer have resolved.
Share:
U.S. FDA Granted Fast Track Designation in 2018
Trial Expected to Enroll 300-400 Patients at Approximately 165 Sites in the U.S. and Europe in Simplified Adaptive Trial Design
Conference Call and Webcast Today at 8:30 a.m. ET
HOUSTON, April 27, 2021 (GLOBE NEWSWIRE) Aravive Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the Company has dosed the first patient in its Phase 3 trial of AVB-500 in platinum resistant ovarian cancer (PROC). The trial is evaluating the efficacy of AVB-500 in combination with paclitaxel (chemotherapy) and the primary endpoint is progression free survival.
Biden has delivered vaccines Now comes the hard part washingtonpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtonpost.com Daily Mail and Mail on Sunday newspapers.